Can Moderna Become a $200 Billion Company in 2022?
Moderna (NASDAQ: MRNA) almost made it to $200 billion in market value this year. The vaccine-giant's shares soared, bringing its market capitalization to a high of $195 billion back in August.
Investors cheered as the company reported billions of dollars in coronavirus-vaccine revenue and sales. But the smiles have turned into frowns in recent weeks amid worries that sales will taper off post-pandemic.
Meanwhile, Moderna has been progressing on clinical trials of strain-specific booster candidates and the development of a potential next-generation COVID-19 vaccine. Now the question is whether booster sales next year and optimism about possible future products could bring the sparkle back to Moderna shares -- and result in a jump in market value next year. Let's take a closer look.
Source Fool.com
